Why Beta-Blockers Can Be Risky in Cardiac Amyloidosis?
At a Glance
Beta-blockers can be difficult to tolerate in cardiac amyloidosis because a stiff heart pumps less blood with each beat and may rely on heart rate to maintain circulation. Lowering heart rate can reduce blood pressure and blood flow, causing dizziness or fatigue, but some patients still need carefully monitored treatment.
In this answer
4 sections
If you have cardiac amyloidosis, you might be confused to hear your cardiologist suggest reducing or stopping your beta-blocker. For decades, beta-blockers have been a cornerstone of treatment for many types of heart disease, including heart attacks and heart failure with a reduced ejection fraction.
However, cardiac amyloidosis changes the mechanics of the heart so dramatically that standard medications often need to be reconsidered [1]. Beta-blockers are not universally banned in amyloidosis, but they can be difficult for many patients to tolerate and must be used with careful, individualized caution [2].
⚠️ Important Safety Warning: Never stop taking a beta-blocker abruptly or adjust your dose on your own. Sudden withdrawal can cause a dangerous rebound in heart rate, spikes in blood pressure, or trigger arrhythmias. Always follow your doctor’s specific tapering plan.
The “Stiff Heart” Problem
Cardiac amyloidosis—whether the AL or ATTR type—is caused by abnormal amyloid proteins depositing in the heart muscle [3]. Over time, these deposits make the walls of the heart thick and stiff [4]. (Note: Amyloidosis can also cause the heart to pump weakly, but the stiffness is a primary hallmark).
In a healthy heart, the muscle easily relaxes between beats to fill up with blood. But a stiff amyloid heart cannot relax or expand properly. This creates what doctors call restrictive physiology [3]. Because the chambers cannot stretch to fill with a normal volume of blood, the amount of blood pumped out with every single squeeze (the stroke volume) is significantly limited [1].
Why Heart Rate Becomes So Important
Your body needs a steady flow of blood per minute to supply oxygen to your organs and maintain your blood pressure. This total volume of blood is called your cardiac output.
Cardiac output is determined by a simple equation:
Cardiac Output = Stroke Volume x Heart Rate
In many standard forms of heart failure, beta-blockers are highly beneficial because they block stress hormones, improve long-term survival, and help control the heart’s workload.
But in cardiac amyloidosis, because the stroke volume is limited by the stiff heart muscle [4], your body may rely much more heavily on maintaining a slightly higher heart rate just to keep your blood pressure stable and your organs supplied with blood [5].
How Beta-Blockers Disrupt the Balance
Beta-blockers are designed to lower heart rate and blood pressure.
When you give a beta-blocker to someone with a stiff, amyloid-infiltrated heart, their heart rate drops. Because their stroke volume cannot easily increase to make up the difference, their total cardiac output and blood pressure can drop too [1]. This reduction in blood flow can lead to challenging side effects, including:
- Worsening fatigue and weakness
- Dizziness or lightheadedness (especially when standing up)
- Exercise intolerance (feeling easily winded during physical activity)
- Low blood pressure (hypotension) [6]
To make matters more complicated, many patients with amyloidosis develop autonomic dysfunction (damage to the nerves that control automatic body functions like blood pressure regulation) [5]. This makes it even harder for the body to fight off the low blood pressure caused by beta-blockers [2]. Furthermore, amyloid deposits can damage the heart’s electrical system, causing conduction problems or a heart rate that is already too slow (bradycardia), making beta-blockers even riskier.
Note: Extreme fast heart rates (tachycardia) are also harmful because they don’t give the stiff heart enough time to fill between beats. The goal is a delicate, personalized balance, not simply “faster is better.”
Are Beta-Blockers Always Forbidden?
No. While doctors generally use these drugs very sparingly in cardiac amyloidosis, they are sometimes necessary [2]. The decision is highly individualized based on your disease stage, amyloid type, ejection fraction, and other health conditions [6].
For example, if you develop an irregular heart rhythm like atrial fibrillation (which is very common in amyloidosis), your doctor may need to use small, carefully monitored doses of a beta-blocker to prevent your heart from beating dangerously fast [7]. However, because rate control is so challenging in amyloidosis, they will weigh this very carefully against the risks of low blood pressure [7]. In atrial fibrillation, your doctor will also evaluate you for blood thinners (anticoagulation) to prevent strokes, and they may discuss “rhythm control” strategies to try to restore a normal heartbeat early in the disease [7].
Always consult with a cardiologist who specializes in amyloidosis before making changes.
When to Seek Immediate Medical Care
While fatigue and mild dizziness should be discussed at your next appointment, seek urgent medical attention if you experience:
- Fainting or loss of consciousness
- Chest pain
- Severe or rapidly worsening shortness of breath
- Confusion
- A persistently very fast or very slow pulse at rest
Common questions in this guide
Why can beta-blockers cause problems in cardiac amyloidosis?
Does having cardiac amyloidosis mean I can never take a beta-blocker?
Should I stop my beta-blocker if I feel dizzy?
Why does a beta-blocker need to be tapered in cardiac amyloidosis?
How are beta-blockers used if someone with cardiac amyloidosis develops atrial fibrillation?
What should I monitor at home while taking a beta-blocker?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Amyloidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Why was my beta-blocker originally prescribed, and does my specific amyloidosis subtype or ejection fraction change how we use it?
- 2.If we are reducing or stopping my beta-blocker, what is the safe tapering plan to avoid rebound side effects?
- 3.What is my personal target resting heart rate, and what specific home blood pressure numbers should prompt me to call the clinic?
- 4.If I develop an irregular heartbeat like atrial fibrillation, do I need blood thinners (anticoagulation), and would rhythm control be an option for me?
- 5.Which of my other current heart or blood pressure medications are appropriate for my amyloidosis, and what benefits and risks should we monitor?
References
References (7)
- 1
Tailoring heart failure management in cardiac amyloidosis.
Duque ER, Tepetes NL, Kourek C, et al.
Heart failure reviews 2026; (31(1)).
PMID: 41957254 - 2
Management of Arrhythmias in Cardiac Amyloidosis.
Giancaterino S, Urey MA, Darden D, Hsu JC
JACC. Clinical electrophysiology 2020; (6(4)):351-361 doi:10.1016/j.jacep.2020.01.004.
PMID: 32327068 - 3
Emerging therapeutic avenues in cardiac amyloidosis.
Golatkar V, Bhatt LK
European journal of pharmacology 2023; (960()):176142 doi:10.1016/j.ejphar.2023.176142.
PMID: 37866746 - 4
New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
Perlini S, Mussinelli R, Salinaro F
Current heart failure reports 2016; (13(6)):267-272 doi:10.1007/s11897-016-0311-y.
PMID: 27900617 - 5
Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
Adam RD, Coriu D, Jercan A, et al.
ESC heart failure 2021; (8(4)):2380-2396 doi:10.1002/ehf2.13443.
PMID: 34089308 - 6
Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy.
Schwarting SK, Bieber T, Davies DR, et al.
Circulation. Heart failure 2025; (18(4)):e011796 doi:10.1161/CIRCHEARTFAILURE.124.011796.
PMID: 39963776 - 7
Atrial fibrillation in the setting of cardiac amyloidosis - A review of the literature.
Bazoukis G, Saplaouras A, Efthymiou P, et al.
Journal of cardiology 2024; (84(3)):155-160 doi:10.1016/j.jjcc.2024.03.008.
PMID: 38565394
This page is for informational purposes only and does not constitute medical advice about beta-blocker use in cardiac amyloidosis. Never stop or change a beta-blocker without an individualized tapering plan from your clinician.